BeOne Medicines AG has announced the full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without the PD-1 inhibitor TEVIMBRA (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results, which include the first interim overall survival analysis, will be presented as a Late-Breaking Abstract Oral Presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026. BeOne Medicines intends to submit supplemental Biologics License Applications for TEVIMBRA to the U.S. FDA and for TEVIMBRA and ZIIHERA to China’s National Medical Products Administration, based on these data. The company also plans to expedite regulatory submissions in its licensed territories.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106659371) on January 06, 2026, and is solely responsible for the information contained therein.
